Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16259091 | 0.79 | ALDH1A1 (0.38) | ESR1HRH4MAPTHCAR3HCAR2 | |
| SCHEMBL5382994 | 0.73 | POLB (0.44) | HRH4HRH1MAPTALDH1A1BAZ2B | |
| SCHEMBL28317413 | 0.69 | — | — | |
| SCHEMBL10138667 | 0.69 | — | — | |
| SCHEMBL13754481 | 0.65 | HRH4 (0.55) | HRH4HRH1BAZ2BFDPS | |
| SCHEMBL14300906 | 0.65 | ESR1 (0.48) | ESR1HRH4HCAR3HCAR2MAPK1 | |
| SCHEMBL12763792 | 0.64 | ESR1 (0.47) | ESR1HRH4MAPTHCAR3HCAR2 | |
| SCHEMBL13045345 | 0.63 | ESR1 (0.40) | ESR1HRH4HCAR3HCAR2KDM6B | |
| SCHEMBL15148233 | 0.63 | FDPS (0.41) | ESR1HRH4MAPTALDH1A1RIPK1 | |
| SCHEMBL2154076 | 0.62 | PDE10A (0.46) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362478-A1 | CD4-MIMETIC SMALL MOLECULES SENSITIZE HUMAN IMMUNODEFICIENCY VIRUS TO VACCINE-ELICITED ANTIBODIES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-12-15 | — | — | US | disclosed |
| US-9403763-B2 | CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-02 | — | — | US | disclosed |
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | CD4, CD14, CCR5 | ESR1 1323/4885HRH4 1388/4885HRH1 1623/4885 |
| US-20160362478-A1 | CD4-MIMETIC SMALL MOLECULES SENSITIZE HUMAN IMMUNODEFICIENCY VIRUS TO VACCINE-ELICITED ANTIBODIES | CD4, CD14, CD81 | ESR1 1476/4885HRH4 1758/4885HRH1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.